Clinical application of different concentration of ropivacaine adductor block in daytime knee arthroscopy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300076485

Enrollment

Unknown

Registered

2023-10-10

Start date

2022-10-01

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adductor block

Interventions

Group 1:15ml 0.15% ropivacaine was injected into the adductor canal

Group 2:15ml 0.2% ropivacaine was injected into the adductor canal

Group 3:15ml 0.25% ropivacaine was injected into the adductor canal

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1) Age 18-70 years old, BMI 22-32 kg /m2; 2) ASA grade I ~ ?; 3) Patients undergoing arthroscopic surgery of the knee.

Exclusion criteria

Exclusion criteria: 1) Patients with knee infection and knee trauma; Patients with anatomic deformity of knee joint. 2) Coagulation dysfunction. 3) heart, brain, liver, kidney and other organs failure. 4) Allergy to local anesthesia drugs. 5) Can not cooperate with mental system disease.

Design outcomes

Primary

Measure	Time frame
Postoperative pain score;Quadriceps muscle strength;	—

Countries

China

Contacts

Public ContactKaihua He

The First Affiliated Hospital of Chongqing Medical University

13908396469@163.com+86 139 0839 6469

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026